Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Phase 2 N=50 Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 63; 42 percentage of participants with response
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=41 TAS-OX for Refractory Metastatic Colon Cancer
Colorectal Neoplasms
Primary: Overall Response Rate — 2.4 months
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 3 N=2,526 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Colorectal Cancer
Primary: Disease-free Survival — 73.4; 76.3 percentage of participants — p=0.12
Phase 2 N=211 Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate — 0.33; 0.38; 0.49 proportion
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=85 Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 3 N=2,710 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7
Primary: Disease-free Survival — 75.5; 77.4 percentage of patients
N/A N=450 Improving Rates of Repeat Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Completion of a Fecal Occult Blood Test (FOBT) — 185; 84 participants
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
N/A N=889 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Anxiety Disorder · Cognitive/Functional Effects · Colorectal Cancer
Primary: Disease-free Survival — 80.3; 73.9 percentage of participants — p=0.02
Phase 2 N=29 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
Metastatic Colorectal Cancer
Primary: Response Rate of Lapatinib/Capecitabine. — 4; 1 participants
Phase 2 N=90 Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Phase 2 N=67 Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0) — 7; 2; 40; 42 percentage of participants
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=385 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
Microsatellite Unstable Colorectal Cancer · Microsatellite Stable Colorectal Cancer · Mismatch Repair Proficient Colorectal Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 40.5; 66.4; 71.1; 3.3 percentage of participants
Phase 3 N=1,987 A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Colorectal Cancer
Primary: Disease-free Survival — 656; 603 Participants — p=0.053
Phase 2 N=69 Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…